Clinical Impact of the KL-6 Concentration of Pancreatic Juice for Diagnosing Pancreatic Masses
Table 1
Patients’ characteristics.
Pancreatic inflammatory lesion
IPMN
IPMC
PDAC
Number of patients (M/F)
12 (8/4)
19 (15/4)
5 (1/4)
34 (18/16)
Mean age, y (range)
65.6 (36–80)
71.7 (55–82)
79.6 (77–83)
69.9 (45–83)
Mean size of mass, mm (range)
—
30.0 (4–60)
28.2 (20–50)
31.6 (6–56)
Tumor marker (serum, SD)
CEA
2.8 ± 2.3
3.6 ± 2.8
2.1 ± 2.0
21.4 ± 70.5
CA19-9
10.4 ± 9.0
9.3 ± 30.9
17.9 ± 17.3
1534.0 ± 3729.2a
Span-1
7.1 ± 5.9
12.5 ± 10.1
38.8 ± 41.6
935.0 ± 4163.4
DUPAN2
33.4 ± 30.8
59.1 ± 80.6
53.6 ± 55.0
2404.7 ± 10451.1
KL-6
249.2 ± 121.9
294.6 ± 210.3
280.4 ± 262.7
453.6 ± 503.7b
Materials of which final diagnosis was obtained by operation or clinical follow-up. compared with pancreatic inflammatory lesion. compared with pancreatic inflammatory lesion.
